The Lancet Regional Health - Western Pacific, Год журнала: 2023, Номер 40, С. 100928 - 100928
Опубликована: Окт. 7, 2023
Язык: Английский
The Lancet Infectious Diseases, Год журнала: 2023, Номер 23(5), С. 556 - 567
Опубликована: Янв. 18, 2023
BackgroundThe global surge in the omicron (B.1.1.529) variant has resulted many individuals with hybrid immunity (immunity developed through a combination of SARS-CoV-2 infection and vaccination). We aimed to systematically review magnitude duration protective effectiveness previous against severe disease caused by variant.MethodsFor this systematic meta-regression, we searched for cohort, cross-sectional, case–control studies MEDLINE, Embase, Web Science, ClinicalTrials.gov, Cochrane Central Register Controlled Trials, WHO COVID-19 database, Europe PubMed from Jan 1, 2020, June 2022, using keywords related SARS-CoV-2, reinfection, effectiveness, infection, presence antibodies, immunity. The main outcomes were reinfection hospital admission or immunity, relative alone, vaccination fewer vaccine doses. Risk bias was assessed Bias In Non-Randomized Studies Interventions Tool. used log-odds random-effects meta-regression estimate protection at 1-month intervals. This study registered PROSPERO (CRD42022318605).Findings11 reporting 15 included. For there 97 estimates (27 moderate risk 70 serious bias). 74·6% (95% CI 63·1–83·5) 12 months. waned 24·7% 16·4–35·5) 153 (78 75 97·4% 91·4–99·2) months primary series 95·3% (81·9–98·9) 6 first booster after most recent vaccination. Against following 41·8% 31·5–52·8) months, while 46·5% (36·0–57·3) months.InterpretationAll within but remained high sustained disease. Individuals had highest durability protection, as result might be able extend period before vaccinations are needed compared who have never been infected.FundingWHO Solidarity Response Fund Coalition Epidemic Preparedness Innovations.
Язык: Английский
Процитировано
478
The Lancet Regional Health - Europe, Год журнала: 2023, Номер 35, С. 100747 - 100747
Опубликована: Окт. 13, 2023
Immunocompromised individuals are not optimally protected by COVID-19 vaccines and potentially require additional preventive interventions to mitigate the risk of severe COVID-19. We aimed characterise describe across immunocompromised groups as pandemic began transition an endemic phase.
Язык: Английский
Процитировано
107
The Lancet Infectious Diseases, Год журнала: 2022, Номер 23(2), С. 167 - 176
Опубликована: Окт. 18, 2022
Язык: Английский
Процитировано
98
Nature, Год журнала: 2024, Номер 626(8001), С. 1094 - 1101
Опубликована: Фев. 21, 2024
Persistent SARS-CoV-2 infections may act as viral reservoirs that could seed future outbreaks
Язык: Английский
Процитировано
66
International Journal of Molecular Sciences, Год журнала: 2023, Номер 24(16), С. 12962 - 12962
Опубликована: Авг. 19, 2023
We are reviewing the current state of knowledge on virological and immunological correlates long COVID, focusing recent evidence for possible association between increasing number SARS-CoV-2 reinfections parallel pandemic COVID. The severity largely depends initial episode; in turn, this is determined both by a combination genetic factors, particularly related to innate immune response, pathogenicity specific variant, especially its ability infect induce syncytia formation at lower respiratory tract. cumulative risk COVID as well various cardiac, pulmonary, or neurological complications increases proportionally infections, primarily elderly. Therefore, cases expected remain high future. Reinfections apparently increase likelihood but less so if they mild asymptomatic children adolescents. Strategies prevent urgently needed, among older adults who have higher burden comorbidities. Follow-up studies using an established case definition precise diagnostic criteria people with without reinfection may further elucidate contribution burden. Although accumulating supports vaccination, before after infection, preventive strategy reduce more robust comparative observational studies, including randomized trials, needed provide conclusive effectiveness vaccination preventing mitigating all age groups. Thankfully, answers not only prevention, also treatment options rates recovery from gradually starting emerge.
Язык: Английский
Процитировано
51
The Journal of Infectious Diseases, Год журнала: 2023, Номер 228(10), С. 1311 - 1313
Опубликована: Авг. 18, 2023
Three and a half years into the coronavirus disease 2019 (COVID-19) pandemic, nature durability of protection against severe acute respiratory syndrome 2 (SARS-CoV-2) still remains unclear. Current COVID-19 mRNA vaccines have been shown to provide minimal infection with XBB variants but substantial disease. However, such appears wane quickly. In contrast, from combination both vaccination infection, termed "hybrid immunity", has be greater in magnitude than that provided by either vaccine immunity or natural alone.
Язык: Английский
Процитировано
49
EBioMedicine, Год журнала: 2023, Номер 92, С. 104585 - 104585
Опубликована: Май 3, 2023
Currently approved COVID-19 vaccines administered parenterally induce robust systemic humoral and cellular responses. While highly effective against severe disease, there is reduced effectiveness of these in preventing breakthrough infection and/or onward transmission, likely due to poor immunity elicited at the respiratory mucosa. As such, has been considerable interest developing novel mucosal that engenders more localised immune responses provide better protection recall site virus entry, contrast traditional vaccine approaches focus on immunity. In this review, we explore adaptive components immunity, evaluate epidemiological studies dissect if conferred by parenteral vaccination or drives differential efficacy acquisition discuss undergoing clinical trials assess key challenges prospects for development.
Язык: Английский
Процитировано
48
Emerging Microbes & Infections, Год журнала: 2023, Номер 12(1)
Опубликована: Март 15, 2023
Язык: Английский
Процитировано
45
Science, Год журнала: 2023, Номер 381(6655), С. 336 - 343
Опубликована: Июль 20, 2023
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOCs) now arise in the context heterogeneous human connectivity and population immunity. Through a large-scale phylodynamic analysis 115,622 Omicron BA.1 genomes, we identified >6,000 introductions antigenically distinct VOC into England analyzed their local transmission dispersal history. We find that six eight largest English lineages were already transmitting when was first reported southern Africa (22 November 2021). Multiple datasets show importation continued despite subsequent restrictions on travel from as result export well-connected secondary locations. Initiation two-stage process can be explained by models country's geography hierarchical network. Our results enable comparison processes drive invasion other VOCs across multiple spatial scales.
Язык: Английский
Процитировано
42
Nature Communications, Год журнала: 2024, Номер 15(1)
Опубликована: Апрель 25, 2024
Abstract An improved understanding of the underlying physicochemical properties respiratory aerosol that influence viral infectivity may open new avenues to mitigate transmission diseases such as COVID-19. Previous studies have shown an increase in pH aerosols following generation due changes gas-particle partitioning buffering bicarbonate ions and carbon dioxide is a significant factor reducing SARS-CoV-2 infectivity. We show here aerostability results from moderate atmospheric concentration (e.g. 800 ppm), effect more marked than observed for relative humidity. model likelihood COVID-19 on ambient CO 2 , concluding even this overall risk. These observations confirm critical importance ventilation maintaining low concentrations indoor environments mitigating disease transmission. Moreover, correlation increased with need be better understood when considering consequences increases levels our atmosphere.
Язык: Английский
Процитировано
22